Blood Diagnostics With Nanoscale Precision

Blood Diagnostics With Nanoscale Precision

Utilizing Artificial Intelligence and Nanotechnology to Enhance Detection

platform

TECHNOLOGY PLATFORM

Arrow DX is developing highly sensitive detection chips that can be incorporated into portable sensors.

The versatility of our technology allows for use in a variety of applications ranging from early disease detection to environmental pollutant detection to quality control in the wine industry.

blood

BLOOD DIAGNOSTICS

The ability to detect small molecules, viruses, bacteria, and proteins in blood is an important tool in the fight against disease. Our proprietary technology allows for an enhanced detection method necessary for the early diagnosis of many diseases such as COVID-19, E.coli, and non-alcoholic fatty liver disease (NAFLD) such that an effective treatment can be found thus making it easier for both the patient and physician.

protein

PROTEIN APPLICATIONS

Protein conformational changes are often a strong indicator of a medicine’s effectiveness on an individual patient. Arrow DX is currently developing methods to apply its technology to further the development of biopharmaceuticals and the pursuit of enhanced personalized medicine.

platform

MACHINE LEARNING

Our mission is to harness the powerful applications of machine learning and predictive analytics to enhance diagnostic medicine. Using proprietary algorithms we are working to develop single protein and metabolite sensitivity.

platform

TECHNOLOGY PLATFORM

Arrow DX is developing highly sensitive detection chips that can be incorporated into portable sensors. The versatility of our technology allows for use in a variety of applications ranging from early disease detection to environmental pollutant detection to quality control in the wine industry.

blood

BLOOD DIAGNOSTICS

The ability to detect small molecules, viruses, bacteria, and proteins in blood is an important tool in the fight against disease. Our proprietary technology allows for an enhanced detection method necessary for the early diagnosis of many diseases such as COVID-19, E.coli, and non-alcoholic fatty liver disease (NAFLD) such that an effective treatment can be found thus making it easier for both the patient and physician.

protein

PROTEIN APPLICATIONS

Protein conformational changes are often a strong indicator of a medicine’s effectiveness on an individual patient. Arrow DX is currently developing methods to apply its technology to further the development of biopharmaceuticals and the pursuit of enhanced personalized medicine.

platform

MACHINE LEARNING

Our mission is to harness the powerful applications of machine learning and predictive analytics to enhance diagnostic medicine. Using proprietary algorithms we are working to develop single protein and metabolite sensitivity.

Our mission is to develop new tools to help researchers and doctors detect chemical and biological entities in the fight against disease.

Our technology is the key to unlocking fast, reliable, and flexible diagnostics for a wide variety of applications ranging from early-stage disease detection to environmental pollutant detection to quality control in the wine industry.

Current News

worldwide-150x150

April 2020

Arrow DX initiates efforts to develop quick, inexpensive, sensitive diagnostics for viruses such as COVID-19, H1N1 as well as bacteria such as E.coli.

target-150x150

June 2020

Arrow Dx presents at the Boston Scientific Connected Patient Challenge VI as a Semi-Finalist.

suit-150x150

August 2021

Arrow Dx chosen to present at the 2021 New England Healthcare Executive Network Summer Social.

suit-150x150

August 2021

David E. Cohen MD-PhD., renowned expert in liver diseases and Chief of Division of Gastroenterology & Endoscopy at Brigham and Women’s Hospital, Harvard Medical School joins the Arrow Dx scientific advisory board.

Current News

worldwide-150x150

June 2020

Arrow DX has been selected as one of the 15 companies that will compete in the 2020 $200K M2D2 Challenge in Lowell, MA in Fall 2020. The 2020 $200K M2D2 Challenge received 250+ applications this year.

target-150x150

April 2020

Arrow DX initiates efforts to develop quick, inexpensive, sensitive diagnostics for viruses such as COVID-19, H1N1 as well as bacteria such as E.coli.

suit-150x150

August 2021

Arrow Dx chosen to present at the 2021 New England Healthcare Executive Network Summer Social.

suit-150x150

August 2021

David E. Cohen MD-PhD., renowned expert in liver diseases and Chief of Division of Gastroenterology & Endoscopy at Brigham and Women’s Hospital, Harvard Medical School joins the Arrow Dx scientific advisory board.

Learn More

About Us

Arrow DX is building highly sensitive chips which will detect chemical and biological molecules with enhanced sensitivity in solution. The versatility of the technology allows its use in a variety of environments.

One of the most important areas that the company is focusing on is the detection of biological and chemical molecules in blood, water, and saliva.

The most important aspects of the technology are its portability, ease of use, and versatility at detecting a wide range of compounds.

Key Collaborators

  • Nicholas Brown, Ph.D., Assistant Teaching Professor in Data Science, Northeastern University

  • Brian Cunningham, Ph.D., Donald Biggar Willet Prof of Engineering, Univ. of Illinois, Urbana-Champaign

Scientific Advisory Board

  • David P. Nunes, MD, Director of Hepatology, Assoc. Professor of Medicine, Boston Univ. School of Medicine

  • Joe DiStefano III, Ph.D., Distinguished Professor of Computer Science and Medicine, University of California, Los Angeles

  • David E. Cohen MD-PhD., Chief of Division of Gastroenterology & Endoscopy at Brigham and Women’s Hospital, Harvard Medical School

Board of Advisors

  • Robert Buzzelli, Senior Managing Director at TeraNova Capital Partners and Shareholder of New World Financial Holdings

  • Brian Christie, Executive Producer at the Boomer Show, Former CNN anchor